A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
Latest Information Update: 26 Apr 2022
At a glance
- Drugs Brentuximab vedotin (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Lymphoma; Lymphoproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Status changed from recruiting to completed according to results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 09 Mar 2013 New trial record